Oncology

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

Investigators sought to measure and attribute out-of-pocket costs to cancer stage and by diagnosis.

Despite offering significant protection against severe COVID-19, patients with cancer, a high-risk group, showed low uptake of booster vaccinations.

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

CK Wang, MD, chief medical officer of COTA, discusses how real-world data help identify disparities and gaps in cancer care.

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.

Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions on the use of these methods of testing, says Eric Lander, MD.

This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help to improve access to clinical trials on a national and local level, explains Eric Lander, MD, of Minnesota Oncology.

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, BCOP, of Robert Wood Johnson University Hospital.

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl Morris Cancer Center.

The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.